SynAct Pharma: Cash Position Further Strengthened - Redeye

Redeye comments on SynAct Pharma's directed share issue of gross cSEK52m. This results in limited dilution (c5%) and prolongs the cash runway into Q3 2027. We are positive about the cash injection as the dilution is very limited while it results in de-risking.

Länk till analysen i sin helhet: https://www.redeye.se/research/1155604/synact-pharma-cash-position-further-strengthened?utm_source=finwire&utm_medium=RSS